Patents by Inventor Sheng-Jiun Wu

Sheng-Jiun Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Monospecific and multispecific anti-TMEFF2 antibodies and their uses
    Patent number: 11866499
    Abstract: The disclosure provided herein relates to monospecific and multispecific anti-TMEFF2 antibodies, and methods of producing and using the described antibodies.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: January 9, 2024
    Assignee: Janssen Biotech, Inc.
    Inventors: Philip Cooper, Robin Ernst, Rajkumar Ganesan, Colleen Kane, Michael Russell, Sanjaya Singh, Sathyadevi Venkataramani, Sheng-Jiun Wu
  • Anti-IL-6 Antibody
    Publication number: 20220048985
    Abstract: Anti-IL-6 antibodies and antirheumatics are useful to treat and suppress IL-6 related conditions, such as rheumatoid arthritis.
    Type: Application
    Filed: November 1, 2021
    Publication date: February 17, 2022
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David M. Marquis, David J. Shealy, Eric Michael Smith, Xiao-yu R. Song, Vedrana Stojanovic-Susulic, Raymond Sweet, Susan Tam, Alain P. Vasserot, Sheng-Jiun Wu, Jing Yang
  • Methods of suppressing rheumatoid arthritis using an anti-IL-6 antibody
    Patent number: 11180549
    Abstract: Anti-IL-6 antibodies and antirheumatics are useful to treat and suppress IL-6 related conditions, such as rheumatoid arthritis.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: November 23, 2021
    Assignees: Janssen Biotech, Inc., Applied Molecular Evolution, Inc
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David M. Marquis, David J. Shealy, Eric Michael Smith, Xiao-yu R. Song, Vedrana Stojanovic-Susulic, Raymond Sweet, Susan Tam, Alain P. Vasserot, Sheng-Jiun Wu, Jing Yang
  • ANTIBODIES SPECIFICALLY BINDING PD-1, TIM-3 OR PD-1 AND TIM-3 AND THEIR USES
    Publication number: 20210277110
    Abstract: The present invention relates to antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Application
    Filed: November 6, 2020
    Publication date: September 9, 2021
    Inventors: Raluca Verona, Gordon Powers, Nina Chi Sabins, Nikki A. DeAngelis, Sandra Santulli-Marotto, Karla R. Wiehagen, Sheng-Jiun Wu, Catherine Ferrante, Enrique Zudaire Ubani
  • Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses
    Patent number: 10894830
    Abstract: The present invention relates to antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: January 19, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Raluca Verona, Gordon Powers, Nina Chi Sabins, Nikki A DeAngelis, Sandra Santulli-Marotto, Karla R Wiehagen, Sheng-Jiun Wu, Catherine Ferrante, Enrique Zudaire Ubani
  • Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof
    Patent number: 10844122
    Abstract: Provided herein are isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof wherein a FN3 domain specifically binds human prostate specific membrane antigen (PSMA) and a second antigen-binding site immunospecifically binds CD3. Also described are fusion proteins and related polynucleotides capable of encoding the provided fusion proteins and, cells expressing the provided fusion proteins. In addition, methods of using the provided isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof are described.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: November 24, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Glenn Anderson, Rosa Cardoso, Michael Diem, Francois Gaudet, Shalom Goldberg, Benjamin Harman, Linus Hyun, Steven Jacobs, Donna Klein, Yingzhe Li, Jinquan Luo, Ronan McDaid, Jill Mooney, Jennifer Nemeth-Seay, Karyn O'Neil, Steven Pomerantz, Galla Chandra Rao, Tracy Spinka-Doms, Alexey Teplyakov, Leopoldo Luistro, Sheng-Jiun Wu
  • Compositions and methods for anti-staphylococcal biologic agents
    Patent number: 10781246
    Abstract: The present disclosure is directed to staphylococcal leukotoxin and hemolysin binding molecules and fusion constructs. The present disclosure is further directed to methods of treating, preventing, and diagnosing staphylococcal infection in a subject using the binding molecules and fusion constructs described herein.
    Type: Grant
    Filed: June 4, 2016
    Date of Patent: September 22, 2020
    Assignees: NEW YORK UNIVERSITY, JANSSEN BIOTECH, INC.
    Inventors: Randall J. Brezski, Anthony S. Lynch, Peter T. Buckley, Jeffrey Fernandez, Jinquan Luo, Thomas J. Malia, Sheng-Jiun Wu, Victor J. Torres
  • Methods of Suppressing Rheumatoid Arthritis Using an Anti-IL-6 Antibody
    Publication number: 20200115445
    Abstract: Anti-IL-6 antibodies and antirheumatics are useful to treat and suppress IL-6 related conditions, such as rheumatoid arthritis.
    Type: Application
    Filed: December 17, 2019
    Publication date: April 16, 2020
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David M. Marquis, David J. Shealy, Eric Michael Smith, Xiao-yu R. Song, Vedrana Stojanovic-Susulic, Raymond Sweet, Susan Tam, Alain P. Vasserot, Sheng-Jiun Wu, Jing Yang
  • MONOSPECIFIC AND MULTISPECIFC ANTI-TMEFF2 ANTIBODIES AND THEIR USES
    Publication number: 20190359711
    Abstract: The disclosure provided herein relates to monospecific and multispecific anti-TMEFF2 antibodies, and methods of producing and using the described antibodies.
    Type: Application
    Filed: May 21, 2019
    Publication date: November 28, 2019
    Applicant: Janssen Biotech, Inc.
    Inventors: Philip Cooper, Robin Ernst, Rajkumar Ganesan, Colleen Kane, Michael Russell, Sanjaya Singh, Sathyadevi Venkataramani, Sheng-Jiun Wu
  • ST2L antagonists and methods of use
    Patent number: 10450377
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: October 22, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Karen Duffy, Natalie Fursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiun Wu
  • COMPOSITIONS AND METHODS FOR ANTI-STAPHYLOCOCCAL BIOLOGIC AGENTS
    Publication number: 20190127444
    Abstract: The present disclosure is directed to staphylococcal leukotoxin and hemolysin binding molecules and fusion constructs. The present disclosure is further directed to methods of treating, preventing, and diagnosing staphylococcal infection in a subject using the binding molecules and fusion constructs described herein.
    Type: Application
    Filed: June 4, 2016
    Publication date: May 2, 2019
    Inventors: Randall J. BREZSKI, Anthony S. LYNCH, Peter T. BUCKLEY, Jeffrey FERNANDEZ, Jinquan LUO, Thomas J. MALIA, Sheng-Jiun WU, Victor J. TORRES
  • ST2L ANTAGONISTS AND METHODS OF USE
    Publication number: 20190062439
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Application
    Filed: March 15, 2018
    Publication date: February 28, 2019
    Inventors: Karen DUFFY, Natalie Pursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiun Wu
  • Anti-PHG-tau antibodies and their uses
    Patent number: 10196440
    Abstract: The present invention relates to anti-PHF-tau antibodies and methods of making and using them.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: February 5, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Christopher Alderfer, Dariusz Janecki, Xuesong Liu, Melissa Murdock, Sheng-Jiun Wu, Marc Mercken, Marc Vandermeeren, Thomas Malia
  • Antibodies Specifically Binding HLA-DR and Their Uses
    Publication number: 20180355043
    Abstract: The present invention relates antibodies or antigen-binding fragments thereof specifically binding HLA-DR, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Application
    Filed: December 16, 2016
    Publication date: December 13, 2018
    Inventors: Christian Martinez, Qiang Chen, Melissa Swiecki, Robert Kuhn, Hong Zhou, Karen Duffy, Stephane Becart, Chichi Huang, Xiefan Lin-Schmidt, Sheng-Jiun Wu, Jeffrey Luo, Galina Obmolova, Robin Ernst
  • ANTI-PHF-TAU ANTIBODIES AND THEIR USES
    Publication number: 20180305445
    Abstract: The present invention relates to anti-PHF-tau antibodies and methods of making and using them.
    Type: Application
    Filed: May 21, 2018
    Publication date: October 25, 2018
    Inventors: Christopher Alderfer, Dariusz Janecki, Xuesong Liu, Melissa Murdock, Sheng-Jiun Wu, Marc Mercken, Marc Vandermeeren, Thomas Malia
  • TOLL-LIKE RECEPTOR 3 ANTAGONISTS
    Publication number: 20180179294
    Abstract: Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.
    Type: Application
    Filed: February 15, 2018
    Publication date: June 28, 2018
    Inventors: Mark Cunningham, Yiqing Feng, Katharine Heeringa, Jinquan Luo, Robert Rauchenberger, Mark Rutz, Lani San Mateo, Robert Sarisky, Raymond Sweet, Fang Teng, Alexey Teplyakov, Sheng-Jiun Wu
  • Anti-PHF-tau antibodies and their uses
    Patent number: 10000559
    Abstract: The present invention relates to anti-PHF-tau antibodies and methods of making and using them.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: June 19, 2018
    Assignee: Janssen Biotech, Inc.
    Inventors: Christopher Alderfer, Dariusz Janecki, Xuesong Liu, Melissa Murdock, Sheng-Jiun Wu, Marc Mercken, Marc Vandermeeren, Thomas Malia
  • ST2L antagonists and methods of use
    Patent number: 9951137
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: April 24, 2018
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Karen Duffy, Natalie Fursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiun Wu
  • Methods of reducing clinical symptoms of viral infection by administering a toll-like receptor 3 antagonist
    Patent number: 9932404
    Abstract: Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: April 3, 2018
    Assignee: Janssen Biotech, Inc.
    Inventors: Mark Cunningham, Yiqing Feng, Katharine Heeringa, Jinquan Luo, Robert Rauchenberger, Mark Rutz, Lani San Mateo, Robert Sarisky, Raymond Sweet, Fang Teng, Alexey Teplyakov, Sheng-Jiun Wu
  • CD123 binding agents and uses thereof
    Patent number: 9850310
    Abstract: Provided herein are antibodies that immunospecifically bind to CD123. Also described are related polynucleotides capable of encoding the provided CD123-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor CD123-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with CD123-expressing cancer and thus may be amenable to treatment with a CD123-specific anti-cancer therapeutic, such as the multispecific antibodies against CD123 and CD3 described herein.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: December 26, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Francois Gaudet, Jennifer F. Nemeth, Ricardo Attar, Benjamin C. Harman, Yingzhe Li, Jinquan Luo, Ronan McDaid, Steven C. Pomerantz, Susan H. Tam, Alexey Teplyakov, John Wheeler, Sheng-Jiun Wu